Science-Driven Innovations

Enabling precision medicine today, accelerating personalized therapies for tomorrow.
Pharmacogenomics and Precision Medicine

Science-Driven Innovations

Enabling precision medicine today, accelerating personalized therapies for tomorrow.

Complete pharmacogenomics testing portfolio

As the leader in pharmacogenomics (PGx), RPRD offers a complete portfolio of leading-edge testing and supporting services. Whether you are looking for a Whole Pharmacogenomics Scan that analyzes nearly all the actionable PGx genetic variants, a customized PGx panel, a targeted panel (CEP72, NUDT15 and TPMT) that guides patient-specific treatment modalities, or a sequencing service on various next-generation sequencing (NGS) platforms, we are the right partner for you.

Pharmacogenomics Testing in CLIA Laboratory
Why implement pharmacogenomics?

In the US, 100,000 deaths occur annually due to adverse drug reactions (ADRs), and 1 out of 5 injuries or deaths occur because of ADRs in hospitalized patients. Implementing pharmacogenomics (PGx) could potentially reduce ADRs-related injuries and deaths.


Dr. Shannon Manzi serves as the Director of the Clinical pharmacogenomics (PGx) Service, and is instrumental in developing a team-based precision medicine program at Boston Children’s Hospital. Dr. Manzi, together with Dr. Scharer, Chief Medical Officer at RPRD, share their hands-on experience in PGx implementation and showcase how the clinical PGx service improves patient outcome and reduces the overall cost of care.


Important pharmacogenetics genes

Learn more about the important pharmacogenetics (PGx) genes. The detail includes how the gene impacts the drug response and a brief summary of the clinical recommendations provided by Clinical Pharmacogenetics Implementation Consortium (CPIC).

News & Updates

On Oct 18th, Dr. Ulrich Broeckel, Founder and CEO of RPRD, together with Dr. Mary Relling, Leader of the Clinical Pharmacogenetics Implementation Consortium (CPIC), will chair the Invited Session 78. Clinical Spotlight: Basic Research to Clinical Implementation: A Multidisciplinary Overview of the Current State and Future Directions of Clinical Pharmacogenomics Testing, at the American Society of Human Genetics 2019 annual meeting in Houston, TX. 


End-to-end solutions to enable precision medicine

We leverage advanced technologies and our decades-long experience in genetics research to bring pharmacogenetics into the mainstream. We empower clinicians with complete solutions, so they can focus on providing better care for their patients.

Evidence-based high-quality solutions

Our PGx solutions are formulated based on the latest clinical practice guidelines, which are supported by rigorous peer-reviewed clinical and scientific evidence.

Genetics in Drug Responses


Our drug development partners trust our academic excellence and decades of scientific research experience in genetics and the impact of genetics on drug responses. Through our continued research in modern technologies and drug R&D, we help our partners pursue personalized therapies to achieve better care for tomorrow.

PGx TestimonialMy team and I are very proud of the tests we offer because they are developed using strong peer-reviewed scientific evidence and the industry’s highest standards. The tests are highly accurate, actionable and ethnicity-unbiased, as they investigate both common and rare variants, and our diagnostic interpretation adheres to the latest clinical guidelines. Our goal is to ensure that patients receive the most up-to-date, comprehensive and accurate results possible.

- Amy Turner, Director of Research and Development

Unlock the power of science

RPRD is accelerating personalized therapies of tomorrow through its long-term commitment to advancing PGx with scientific breakthroughs and innovations.

PGx Diagnostic Solutions

RPRD’s experience in precision medicine and its CLIA-certified laboratory offer a wide range of PGx diagnostic services to meet your unique needs.